User profiles for "author:R A Scolyer"

Richard A Scolyer

Melanoma Institute Australia, The University of Sydney, Royal Prince Alfred Hospital
Verified email at sswahs.nsw.gov.au
Cited by 85973

Cutaneous melanoma

JF Thompson, RA Scolyer, RF Kefford - The Lancet, 2005 - thelancet.com
Episodic exposure of fair-skinned individuals to intense sunlight is thought to be responsible
for the steadily increasing melanoma incidence worldwide over recent decades. Rarely …

Resistance to PD1/PDL1 checkpoint inhibition

JS O'Donnell, GV Long, RA Scolyer, MWL Teng… - Cancer treatment …, 2017 - Elsevier
For the first time in decades, patients with difficult-to-treat cancers such as advanced stage
metastatic melanoma are being offered a glimpse of hope in the form of immunotherapies …

The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary …

DE Elder, BC Bastian, IA Cree… - … of pathology & …, 2020 - meridian.allenpress.com
Context.—There have been major advances in the understanding of melanoma since the
last revision of the World Health Organization (WHO) classification in 2006. Objective.—To …

Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

JE Gershenwald, RA Scolyer, KR Hess… - CA: a cancer journal …, 2017 - Wiley Online Library
Answer questions and earn CME/CNE To update the melanoma staging system of the
American Joint Committee on Cancer (AJCC) a large database was assembled comprising> …

Whole-genome landscapes of major melanoma subtypes

NK Hayward, JS Wilmott, N Waddell, PA Johansson… - Nature, 2017 - nature.com
Melanoma of the skin is a common cancer only in Europeans, whereas it arises in internal
body surfaces (mucosal sites) and on the hands and feet (acral sites) in people throughout …

Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

GV Long, AM Menzies, AM Nagrial… - Journal of Clinical …, 2011 - ascopubs.org
Purpose To assess the frequency and type of oncogenic BRAF mutations in metastatic
melanoma and correlate BRAF status with clinicopathologic features and outcome. Patients …

[HTML][HTML] Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

H Shi, G Moriceau, X Kong, MK Lee, H Lee… - Nature …, 2012 - nature.com
The development of acquired drug resistance hampers the long-term success of B-RAF
inhibitor therapy for melanoma patients. Here we show V600E B-RAF copy-number gain as …

[HTML][HTML] Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma

CG Lian, Y Xu, C Ceol, F Wu, A Larson, K Dresser… - Cell, 2012 - cell.com
DNA methylation at the 5 position of cytosine (5-mC) is a key epigenetic mark that is critical
for various biological and pathological processes. 5-mC can be converted to 5 …

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

JJ Luke, P Rutkowski, P Queirolo, M Del Vecchio… - The Lancet, 2022 - thelancet.com
Background Pembrolizumab prolongs progression-free and overall survival among patients
with advanced melanoma and recurrence-free survival in resected stage III disease …

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

GV Long, V Atkinson, S Lo, S Sandhu… - The Lancet …, 2018 - thelancet.com
Background Nivolumab monotherapy and combination nivolumab plus ipilimumab increase
proportions of patients achieving a response and survival versus ipilimumab in patients with …